June 30, 2020
June 18, 2020
Michigan Medicine Ranked No. 5 Hospital in the U.S., No 15 in the World by Newsweek
Michigan Medicine has earned the No. 15 spot in Newsweek’s 2020 World’s Best Hospitals list. The institution also came in fifth in the United States and was named top hospital in Michigan.
June 10, 2020
COVID-19 IgG Serology Testing Now Available!
Serology testing for SARS-CoV-2 is now available for ordering. A separate process for testing and screening of health care workers and Michigan Medicine affiliates will be communicated in the coming weeks.
February 20, 2020
USCAP 2020 Conference
USCAP has its eyes on you as you navigate the exhibit hall, posters, platform sessions special courses, Long Course on Major Advances in the Diagnosis and Management of Breast Diseases, short courses, interactive microscopy courses...
February 10, 2020
FSP Annual Meeting 2020
Once again, MLabs will be exhibiting at The FSP’s 46th Annual Pathology Conference: Updates and Practical Approaches in Pathology is designed to provide pathologists with education surrounding...
October 13, 2019
ASHG 2019 Conference
The ASHG 2019 Annual Meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. It will be held in...
September 19, 2019
MLabs to be renamed Michigan Medicine Laboratories
Reference laboratory services available through Michigan Medicine now have a new name: Michigan Medicine Laboratories.
August 14, 2019
MLabs offers NGS to detect PIK3CA mutation targeted by New Metastatic Breast Cancer Treatment
Many patients living with metastatic breast cancer (mBS) now have a new treatment option. In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...
June 17, 2019
MLabs Approved to Participate in NCI-MATCH Clinical Trial
MLabs, and the Department of Pathology laboratories at Michigan Medicine, recognized leaders for advanced diagnostic testing, are now participating in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial.
January 22, 2019
MLabs NGS Panels Detects NTRK Fusion Genes in Select Solid Tumor Patients for FDA-approved Vitrakvi® (larotrectinib) Therapy
MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions...